

Amendments to the Claims:

This listing of claims will replace all prior versions of claims in the application.

1. (Currently Amended) A method for treating a patient having liver cancer, said method comprising administering to said patient (i) an effective amount of a pharmaceutical composition comprising a mammalian asialo-interferon, and (ii) a second anti-neoplastic therapy.
2. (Original) The method of claim 1, wherein said liver cancer expresses the asialo-glycoprotein receptor.
3. (Original) The method of claim 2, wherein said liver cancer overexpresses the asialo-glycoprotein receptor.
4. (Original) The method of claim 1, wherein said liver cancer is selected from the group consisting of diffuse-type hepatocellular carcinoma, febrile-type hepatocellular carcinoma, cholestatic hepatocellular carcinoma, hepatoblastoma, hepatoid adenocarcinoma, and focal nodular hyperplasia.
5. (Original) The method of claim 1, wherein said asialo-interferon is a human asialo-interferon.
6. (Original) The method of claim 5, wherein said human asialo-interferon is an asialo-interferon- α .
7. (Original) The method of claim 5, wherein said human asialo-interferon is an asialo-interferon- β or an asialo-interferon- γ .

8. (Original) The method of claim 1, wherein said effective amount is 0.05-1.5 mg/week.

9. (Canceled)

10. (Currently Amended) The method of claim ~~[[9]]~~1, wherein said second anti-neoplastic therapy is chemotherapy or radiation therapy.

11. (Currently Amended) A method for treating a patient having liver cancer, said method comprising the steps of:

(a) testing said liver cancer for expression of an asialo-glycoprotein receptor; and

(b) if said testing step (a) is indicative that said liver cancer expresses an asialo-glycoprotein receptor, administering to said patient (i) an effective amount of a composition comprising a mammalian asialo-interferon, and (ii) a second anti-neoplastic therapy.

12. (Original) The method of claim 11, wherein said testing in step (a) comprises performing a liver biopsy.

13. (Original) The method of claim 11, wherein said liver cancer overexpresses the asialo-glycoprotein receptor.

14. (Currently Amended) The method of claim ~~[[13]]~~11, wherein said testing in step (a) comprises non-invasive imaging of the liver of said patient.

15. (Original) The method of claim 11, wherein said liver cancer is selected from the group consisting of diffuse-type hepatocellular carcinoma, febrile-type

hepatocellular carcinoma, cholestatic hepatocellular carcinoma, hepatoblastoma, hepatoid adenocarcinoma, and focal nodular hyperplasia.

16. (Original) The method of claim 11, wherein said asialo-interferon is a human asialo-interferon.

17. (Original) The method of claim 16, wherein said human asialo-interferon is asialo-interferon- α .

18. (Original) The method of claim 16, wherein said human asialo-interferon is asialo-interferon- β or asialo-interferon- γ .

19. (Original) The method of claim 11, wherein said effective amount is 0.05-1.5 mg/week.

20. (Canceled)

21. (Currently Amended) A method for treating a metastatic cancer of the liver, said method comprising administering to ~~said~~ a patient with said metastatic cancer (i) an effective amount of a pharmaceutical composition comprising a mammalian asialo-interferon, and (ii) a second anti-neoplastic therapy.

22. (Original) The method of claim 21, wherein said metastatic cancer is selected from the group consisting of metastatic prostate cancer, metastatic colorectal cancer, metastatic breast cancer, metastatic lung cancer, metastatic pancreatic cancer, metastatic melanoma, metastatic leukemia, and metastatic lymphoma.

23. (Currently Amended) The method of claim 21, wherein said human asialo-interferon is asialo-interferon- α , asialo-interferon- β_2 or asialo-interferon- γ .

24. (New) The method of claim 11, wherein said second anti-neoplastic therapy is chemotherapy or radiation therapy.

25. (New) The method of claim 21, wherein said second anti-neoplastic therapy is chemotherapy or radiation therapy.